David Riddle, MD
Internal Medicine · Birmingham, ALNPI 1215102660
Payments from drug & device makers
Across 404 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$688
- AbbVie$672
- Pfizer$574
- Gilead$515
- Johnson & Johnson$382
- Amgen$327
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,976100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $688 |
| AbbVie(2 entities) | 51 | $672 |
| Pfizer | 38 | $574 |
| Gilead | 34 | $515 |
| Johnson & Johnson | 27 | $382 |
| Amgen | 21 | $327 |
| Lilly USA, LLC | 25 | $326 |
| Viiv Healthcare Company | 19 | $321 |
| Astellas Pharma US Inc | 19 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $237 |
| Eisai Inc. | 12 | $169 |
| Abbott | 7 | $154 |
| Amarin Pharma, Inc. | 9 | $137 |
| GSK | 10 | $134 |
| Dexcom, Inc. | 7 | $125 |
| Merck | 8 | $100 |
| Kowa Pharmaceuticals America, Inc. | 7 | $90 |
| Boehringer Ingelheim | 5 | $88 |
| Novartis | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Genentech USA, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 4 | $51 |
| Avanir Pharmaceuticals, Inc. | 3 | $41 |
| Boston Scientific | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 3 | $36 |
| Exact Sciences | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Shield Therapeutics Inc | 1 | $23 |
| Endogastric Solutions, Inc | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Pulmonx Corporation | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $12 |
How this compares
$5,990 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $166,764 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $106,026 |
| JardianceEmpagliflozin | 69 | $86,983 |
| MounjaroTirzepatide | 64 | $74,957 |
| TrulicityDulaglutide | 46 | $72,333 |
| RybelsusSemaglutide | 32 | $56,000 |
| EliquisApixaban | 49 | $39,315 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $28,579 |
| FarxigaDapagliflozin Propanediol | 19 | $25,182 |
| InvokanaCanagliflozin | 13 | $22,947 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,096 |
| XareltoRivaroxaban | 26 | $15,641 |
| MyrbetriqMirabegron | 13 | $13,292 |
| LinzessLinaclotide | 15 | $10,516 |
| Rosuvastatin Calcium | 396 | $8,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $688 | $222,764138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $326 | $147,289110 claims |
| GileadBiktarvy | $515 | $106,02623 claims |
| Boehringer IngelheimJardiance | $88 | $86,98369 claims |
| PfizerEliquis | $574 | $39,31549 claims |
| Johnson & JohnsonInvokana, Xarelto | $382 | $38,58739 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $134 | $27,13840 claims |
| AstraZenecaFarxiga | $13 | $25,18219 claims |
| Astellas Pharma US IncMyrbetriq | $273 | $13,29213 claims |
| AbbVieLinzess | $672 | $10,51615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.